There is only one Cardiolite

Faces of Coronary Artery Disease

Face the Facts

Coronary artery disease (CAD) is the leading cause of death in the U.S. for both men and women.1 Optimal diagnostic and management strategies for CAD may vary depending on gender, race and other co-existing conditions.

In patients with known or suspected coronary artery disease, myocardial perfusion imaging is often used to determine the presence and severity of physiologically significant coronary artery disease.2

Cardiolite® IS wherever CAD is, within the Spectrum of CAD, whether it is:

Diabetes and CAD

In patients with diabetes, CAD may be more extensive at diagnosis and may be "silent."3

CAD is a major cause of morbidity and mortality in this patient population; it is the cause of death in at least 70% of all diabetic patients.3

Patients with evidence of exercise-induced ischemia in stress studies after sustaining myocardial infarction are at risk for recurrent myocardial infarctions and cardiac death.3

Cardiolite® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection) was used in both the DIAD (Detection and Treatment of Myocardial Ischemia in Asymptomatic Patients with Diabetes) and the BARI-2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) studies to identify CAD in these patient cohorts.4,5

Women and CAD

More women than men die from cardiovascular disease. In 2006, 432.7k women died vs. 398.6k men6

Effective diagnosis of CAD in women requires the recognition that not all women present with the same symptoms. Some women experience silent ischemia. Others attribute symptoms to other medical conditions which can delay care.7

For more information on Cardiolite®’s long clinical history in helping healthcare providers risk stratify their patients, please click to our Spectrum of CAD.

Click here to view footnotes
  1. National Institutes of Health, National Heart, Lung, and Blood Institute. Coronary Artery Disease: Who Is At Risk. Accessed April 13, 2010.
  2. Strauss et al. Sept. 2008. Procedure Guideline for Myocardial Perfusion Imaging 3.3 Journal of Nuclear Medicine Technology 2008;36,3:155-161.
  3. Tabibiazar R, Edelman S. Silent Ischemia in People With Diabetes:
    A Condition That Must Be Heard. Clinical Diabetes 2003:21:1-9.
  4. DIAD, Young et al. Cardiac Outcomes After Screening for Asymptomatic Coronary Artery Disease in Patients With Type 2 Diabetes
    The DIAD Study: A Randomized Controlled Trial, JAMA. 2009;301:15;1547-55.
  5. BARI-2D, Hypotheses, Design and Methods for the Bypass Angioplasty Revascularization Investigation 2 Diabetes Trial. Am J Cardiol 2006;97(12A):9G-19G.
  6. American Heart Association. Heart Disease and Stroke Statistics—2010 Update.
    Accessed April 13, 2010.
  7. Women Heart The National Coalition for Women with Heart Disease - Are you having a heart attack? April 13, 2010.


Lantheus Medical Imaging

Indications and Usage for Cardiolite®:
Myocardial Imaging:  CARDIOLITE® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection), is a myocardial perfusion agent that is indicated for detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and infarction (non-reversible defects), in evaluating myocardial function and developing information for use in patient management decisions.  CARDIOLITE® evaluation of myocardial ischemia can be accomplished with rest and cardiovascular stress techniques (e.g. exercise or pharmacologic stress in accordance with the pharmacologic stress agent’s labeling).

None known.


CARDIOLITE® has been rarely associated with acute severe allergic and anaphylactic events of angioedema and generalized urticaria.  In some patients the allergic symptoms developed on the second injection during CARDIOLITE® imaging.  The most frequently reported adverse events include headache, chest pain/angina, ST segment changes on ECG, nausea, and abnormal taste and smell.

Infrequently, death has occurred 4 to 24 hours after Tc99m Sestamibi use and is usually associated with exercise stress testing (See Section 5.2). Pharmacologic induction of cardiovascular stress may be associated with serious adverse events such as myocardial infarction, arrhythmia, hypotension, bronchoconstriction and cerebrovascular events.

In studying patients in whom cardiac disease is known or suspected, care should
be taken to assure continuous monitoring and treatment in accordance with safe,
accepted clinical procedure.

Caution should be exercised and emergency equipment should be available when administering CARDIOLITE®.

Before administering CARDIOLITE® patients should be asked about the possibility of allergic reactions to either CARDIOLITE® or MIRALUMA®.
MIRALUMA® is an identical compound used in breast imaging.

The contents of the vial are intended only for use in the preparation of Technetium Tc99m Sestamibi and are not to be administered directly to the patient without first undergoing the preparative procedure.

Please see full Prescribing Information: Cardiolite® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection)

Indications and Usage for Thallous Chloride Tl 201 Injection:
Thallous Chloride TI 201 Injection may be useful in myocardial perfusion imaging using either planar or SPECT (Single Photon Computed Tomography) techniques for the diagnosis and localization of myocardial infarction.  It may also have prognostic value regarding survival, when used in the clinically stable patient following the onset of symptoms of an acute myocardial infarction, to assess the site and size of the perfusion defect.

Thallous Chloride TI 201 Injection may also be useful in conjunction with exercise stress testing as an adjunct in the diagnosis of ischemic heart disease (atherosclerotic coronary artery disease).

It is usually not possible to differentiate recent from old myocardial infarction, or to differentiate between recent myocardial infarction and ischemia.

Thallous Chloride TI 201 is indicated also for the localization of sites of parathyroid hyperactivity in patients with elevated serum calcium and parathyroid hormone levels.  It may also be useful in pre-operative screening to localize extrathyroidal and mediastinal sites of parathyroid hyperactivity and for postsurgical reexamination.  Thallous Chloride Tl 201 Injection has not been adequately demonstrated to be effective for the localization of normal parathyroid glands.


Important Safety Information:
 Following the administration of Thallous Chloride Tl 201  Injection, adverse anaphylactoid reactions have been reported (characterized by cardiovascular, respiratory, and cutaneous symptoms), some severe enough to require treatment.  Hypotension, pruritus, flushing and diffuse rash which responds to antihistamines have been reported.  Other reported events include itching, nausea/vomiting, mild diarrhea, tremor, shortness of breath, chills, fever, conjunctivitis, sweating and blurred vision.

In studying patients in whom myocardial infarction or ischemia is known or suspected, care should be taken to assure continuous clinical monitoring and treatment in accordance with safe, accepted procedure.  Exercise stress testing should be performed only under the supervision of a qualified physician and in a laboratory equipped with appropriate resuscitation equipment.
The vial stopper contains dry natural rubber latex and may cause allergic reactions in providers or patients who are sensitive to latex.

Data are not available concerning the effect of marked alterations in blood glucose, insulin, or pH (such as is found in diabetes mellitus) on the quality of Thallous ­Chloride TI 201 Injection scans.  Attention is directed to the fact that thallium is a potassium analog, and since the transport of potassium is affected by these factors, the possibility exists that the thallium may likewise be affected.


The patient dose should be measured by a suitable radioactivity calibration system immediately prior to administration.

Thallous Chloride TI 201 Injection, as all radioactive materials, must be handled with care and used with appropriate safety measures to minimize external radiation exposure to patients and to clinical personnel. 

Radiopharmaceuticals should be used only by physicians who are qualified by training and experience in the safe use and handling of radionuclides.

Please see full Prescribing Information: Thallous Chloride Tl 201 Injection